Faster and cheaper. Central European CRO market

Central Europe (CE) is becoming a new emerging market for CROs (Clinical Research Organizations). Fast growing outsourcing of clinical studies in CE region creates new opportunities for pharma and biotech companies facing with cost and time consuming process of drug delivery to the market.

The basic advantages of Central European CRO market are:

• Exclusively beneficial cost/quality ratio;
• Effectiveness of recruitment / fast recruitment;
• High quality of clinical research, availability of high skilled personnel;
• Reasonable prices.

"In my opinion as well as in the opinion of  other professionals conducting clinical researches, CEE countries guarantee effective recruitment sufficient number of patients, high quality of data and cost effectiveness both for innovative products as well as for biosimilars. A key to success is a though, proper process of feasibility and individual planning for each trial" - points out Mariusz Olejniczak, General Manager (Poland) and Chief Operating Officer - Late Stage Projects, Assign Group. Poland is the biggest player on this market, but Czech Republic and Hungary are placed not too far behind. "In Hungary the clinical researches are of exceptional quality. We have highly qualified and reliable professionals, and the region has a long history of clinical development, making it easier to find and train skilled investigators. The authorization process is transparent and compliant with EU guidelines, and also the GCP regulations are incorporated in applicable legislations. The saturation of competing trials within the region compared to other, more developed markets is lower and as the enrolment is fast and the compliance is high, considerable savings can be achieved. The number of well-organized site management organizations and experienced local and regional CROs are increasing" - said  Dr. István SZEMERÉDI, General Manager, Cortex PS (Hungary). According to Marek Kiecana, Chairman of  KCR S.A (Poland), "quality and speed of conducting clinical researches are much better than in the US or Western Europe. The Central - Eastern European region (CEE) was repeatedly subject to audits by the US agency FDA ( Food and Drug Administration), which based on own audits carried out around the world, proved, that quality of research is the best in the CEE region, thus better than in the US, Western Europe or Asia. If it comes to recruitment's speed, in clinical trials in oncology or central nervous system diseases,  recruitment's speed should be ca 5-10 times higher than in the US or Western Europe"

Presenting of clinical researches opportunities in Central Europe is one of the main goals of BioForum (www.cebioforum.com) – Central European Forum of Biotechnology and Innovative BioEconomy, held in Brno (Czech Republic) 23-24th May, 2012. The most dynamic and representative CRO companies from the region will present their capabilities during this event. It will be a perfect occasion for all biotech and pharma companies interested in all phases of clinical researches to come into direct contacts with representatives of this sector. There will be an opportunity to meet companies involved in such research on exhibition or during BioPartnering. BioForum is the biggest and the most important event in Central Europe dedicated to the biotech and pharma industry. Starting in the year 2000 its main aim is creation and development of a cooperation platform between the companies from the life science sector in the CE region. The creator and the main organizer of BioForum is Bio-Tech Consulting Ltd. (www.biotechconsulting.pl)

BioForum - Central European Forum of Biotechnology & Innovative BioEconomy

together with accompanying events will be held on

23-24th of May 2012 in the Conference Centre BVV Trade Fairs in Brno (Czech Republic).

more: www.cebioforum.com